Patents Assigned to Vaxiion Therapeutics, Inc.
-
Patent number: 9017986Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.Type: GrantFiled: August 1, 2013Date of Patent: April 28, 2015Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger Sabbadini, Neil Berkley, Mark Surber, Robert Klepper
-
Publication number: 20130337545Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.Type: ApplicationFiled: August 1, 2013Publication date: December 19, 2013Applicant: Vaxiion Therapeutics, Inc.Inventors: ROGER SABBADINI, Neil Berkley, Mark Surber, Robert Klepper
-
Patent number: 8524484Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.Type: GrantFiled: March 5, 2012Date of Patent: September 3, 2013Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Matthew J. Giacalone
-
Publication number: 20130210121Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.Type: ApplicationFiled: December 11, 2012Publication date: August 15, 2013Applicant: VAXIION THERAPEUTICS, INC.Inventor: Vaxiion Therapeutics, Inc.
-
Publication number: 20120252099Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.Type: ApplicationFiled: March 5, 2012Publication date: October 4, 2012Applicant: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Matthew J. Giacalone
-
Publication number: 20120207754Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.Type: ApplicationFiled: February 15, 2012Publication date: August 16, 2012Applicant: Vaxiion Therapeutics, Inc.Inventors: Matthew J. Giacalone, Michael J. Newman
-
Publication number: 20120142079Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.Type: ApplicationFiled: November 11, 2011Publication date: June 7, 2012Applicant: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Robert Klepper
-
Publication number: 20120135503Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.Type: ApplicationFiled: November 11, 2011Publication date: May 31, 2012Applicant: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
-
Patent number: 8129166Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.Type: GrantFiled: June 4, 2008Date of Patent: March 6, 2012Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
-
Patent number: 8101396Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.Type: GrantFiled: March 16, 2007Date of Patent: January 24, 2012Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Robert Klepper
-
Publication number: 20110281330Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.Type: ApplicationFiled: March 16, 2007Publication date: November 17, 2011Applicant: VAXIION THERAPEUTICS, INC.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
-
Patent number: 7871815Abstract: Disclosed herein is a rhamnose-inducible expression vector.Type: GrantFiled: October 11, 2006Date of Patent: January 18, 2011Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
-
Publication number: 20100112670Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.Type: ApplicationFiled: June 23, 2009Publication date: May 6, 2010Applicant: Vaxiion Therapeutics, Inc.Inventors: Matthew J. Giacalone, Stanley Maloy, Shingo Tsuji
-
Publication number: 20090011490Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.Type: ApplicationFiled: June 4, 2008Publication date: January 8, 2009Applicant: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
-
Publication number: 20090004744Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.Type: ApplicationFiled: April 30, 2008Publication date: January 1, 2009Applicant: Vaxiion Therapeutics, Inc.Inventors: Mark W. Surber, Roger Sabbadini, Neil Berkley
-
Patent number: 7396822Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.Type: GrantFiled: April 26, 2004Date of Patent: July 8, 2008Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
-
Patent number: 7183105Abstract: Th invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.Type: GrantFiled: May 28, 2002Date of Patent: February 27, 2007Assignee: Vaxiion Therapeutics, Inc.Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber